NAFLD and diabetes mellitus

[1]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[2]  P. Aschner.  F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .

[3]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[4]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[5]  Philippe Lehert,et al.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.

[6]  J. Reinus,et al.  Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. , 2016, Clinics in liver disease.

[7]  E. Bugianesi.  EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? , 2016, Diabetologia.

[8]  Gretchen A. Stevens,et al.  Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants , 2016, Lancet.

[9]  B. Motta,et al.  The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage , 2016, Hepatology.

[10]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[11]  B. Staels,et al.  Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. , 2016, Annual review of physiology.

[12]  K. Cusi,et al.  Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes , 2016, Diabetes Care.

[13]  Chia-Wen Lu,et al.  The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality , 2016, Medicine.

[14]  E. Bugianesi,et al.  Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. , 2016, Annual review of medicine.

[15]  C. Sirlin,et al.  Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE , 2016, Alimentary pharmacology & therapeutics.

[16]  A. Hofman,et al.  Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study , 2016, Hepatology.

[17]  J. Shelton,et al.  Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. , 2015, The Journal of clinical investigation.

[18]  Mark D. Meisinger,et al.  Time course of postprandial hepatic phosphorus metabolites in lean, obese, and type 2 diabetes patients. , 2015, The American journal of clinical nutrition.

[19]  Siddharth Singh,et al.  Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis , 2015, Hepatology.

[20]  Aijaz Ahmed,et al.  Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[22]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[23]  M. Carstensen,et al.  Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. , 2015, Cell metabolism.

[24]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[25]  M. Birnbaum,et al.  Hepatic Insulin Signaling is Dispensable for Suppression of Glucose Output by Insulin in Vivo , 2015, Nature Communications.

[26]  B. Neuschwander‐Tetri,et al.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD , 2015, Diabetes Care.

[27]  Vincent Wai-Sun Wong,et al.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study , 2015, Gut.

[28]  Z. Goodman,et al.  Current efforts and trends in the treatment of NASH. , 2015, Journal of hepatology.

[29]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[30]  G. Shulman,et al.  Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats , 2015, Science.

[31]  Ashwani K. Singal,et al.  Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases , 2015, Journal of clinical and translational hepatology.

[32]  M. Orho-Melander,et al.  Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. , 2015, Journal of hepatology.

[33]  Giulio Marchesini,et al.  Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[34]  K. Petersen,et al.  Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes , 2015, Cell.

[35]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[36]  F. Pattou,et al.  Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study , 2014, Annals of surgery.

[37]  W. Oberaigner,et al.  Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria , 2014, BMC Public Health.

[38]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[39]  M. Yeh,et al.  Pathological features of fatty liver disease. , 2014, Gastroenterology.

[40]  A. McCullough,et al.  Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients☆ , 2014, BBA clinical.

[41]  G. Shulman.  Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. , 2014, The New England journal of medicine.

[42]  M. Febbraio,et al.  Integrated Control Of Hepatic Lipogenesis Vs. Glucose Production Requires FoxO Transcription Factors , 2014, Nature Communications.

[43]  B. Staels,et al.  GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes , 2014, Expert opinion on investigational drugs.

[44]  U. Nöthlings,et al.  Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer , 2014, Hepatology.

[45]  G. Shulman,et al.  Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans , 2014, Proceedings of the National Academy of Sciences.

[46]  N. Stefan,et al.  Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[47]  M. Orho-Melander,et al.  A population-based study on the prevalence of NASH using scores validated against liver histology. , 2014, Journal of hepatology.

[48]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[49]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[50]  J. Fallowfield,et al.  Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. , 2014, Journal of hepatology.

[51]  E. Moser,et al.  Lower Fasting Muscle Mitochondrial Activity Relates to Hepatic Steatosis in Humans , 2014, Diabetes Care.

[52]  Y. Mao,et al.  Diabetes Mellitus Is Associated with Hepatocellular Carcinoma: A Retrospective Case-Control Study in Hepatitis Endemic Area , 2013, PloS one.

[53]  Laurent Castera,et al.  Noninvasive evaluation of NAFLD , 2013, Nature Reviews Gastroenterology &Hepatology.

[54]  A. Wree,et al.  From NAFLD to NASH to cirrhosis—new insights into disease mechanisms , 2013, Nature Reviews Gastroenterology &Hepatology.

[55]  H. Tilg,et al.  Non-alcoholic steatohepatitis: a microbiota-driven disease , 2013, Trends in Endocrinology & Metabolism.

[56]  A. Belfiore,et al.  Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment , 2013, International journal of molecular sciences.

[57]  K. Matsuda,et al.  A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity , 2013, Nature.

[58]  C. Anderwald,et al.  Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[59]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[60]  Fabio Pellegrini,et al.  Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review , 2013, PloS one.

[61]  B. Graubard,et al.  Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States , 2013, The American Journal of Gastroenterology.

[62]  S. Wild,et al.  Resolution of fatty liver and risk of incident diabetes. , 2013, The Journal of clinical endocrinology and metabolism.

[63]  D. Mathis.  Immunological goings-on in visceral adipose tissue. , 2013, Cell metabolism.

[64]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[65]  G. Hotamisligil,et al.  Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. , 2013, Cell metabolism.

[66]  Rohit Loomba,et al.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. , 2013, Journal of diabetes and its complications.

[67]  R. DeFronzo,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.

[68]  J. Olefsky,et al.  The Origins and Drivers of Insulin Resistance , 2013, Cell.

[69]  F. Kronenberg,et al.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus , 2013, Nature Medicine.

[70]  H. Tilg,et al.  Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective , 2013, Archivum Immunologiae et Therapiae Experimentalis.

[71]  M. Abraham,et al.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.

[72]  S. Klein,et al.  Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. , 2012, Gastroenterology.

[73]  J. Hardies,et al.  Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[74]  G. Shulman,et al.  Mechanisms for Insulin Resistance: Common Threads and Missing Links , 2012, Cell.

[75]  C. Kahn,et al.  Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1 , 2012, Nature Medicine.

[76]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[77]  M. Osaki,et al.  Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression. , 2011, Cytokine.

[78]  Christopher D. Williams,et al.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial , 2011, Hepatology.

[79]  M. Goran,et al.  Subcutaneous Adipose Tissue Macrophage Infiltration Is Associated With Hepatic and Visceral Fat Deposition, Hyperinsulinemia, and Stimulation of NF-κB Stress Pathway , 2011, Diabetes.

[80]  M. Roden,et al.  The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. , 2011, Trends in pharmacological sciences.

[81]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[82]  Xianlin Han,et al.  Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease , 2011, Proceedings of the National Academy of Sciences.

[83]  K. Petersen,et al.  Apolipoprotein CIII Overexpressing Mice Are Predisposed to Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance , 2011, Hepatology.

[84]  R. Rector,et al.  Mitochondria and redox signaling in steatohepatitis. , 2011, Antioxidants & redox signaling.

[85]  T. Saibara,et al.  Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[86]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[87]  Ewald Moser,et al.  Liver ATP Synthesis Is Lower and Relates to Insulin Sensitivity in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[88]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[89]  N. Sattar,et al.  Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data , 2010, Hepatology.

[90]  S. Kahn,et al.  Insulin Resistance is the Best Predictor of the Metabolic Syndrome in Subjects With a First‐Degree Relative With Type 2 Diabetes , 2010, Obesity.

[91]  H. Tilg,et al.  Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression , 2010, Gut.

[92]  K. Schechtman,et al.  Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. , 2010, Gastroenterology.

[93]  Scott Harmsen,et al.  Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study , 2010, The American Journal of Gastroenterology.

[94]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[95]  Nick V. Grishin,et al.  A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis , 2009, The Journal of Biological Chemistry.

[96]  Z. Goodman,et al.  Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[97]  Ewald Moser,et al.  Abnormal hepatic energy homeostasis in type 2 diabetes , 2009, Hepatology.

[98]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[99]  W. Coyle,et al.  The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.

[100]  Ross J. Harris,et al.  Alanine Aminotransferase, γ-Glutamyltransferase, and Incident Diabetes , 2009, Diabetes Care.

[101]  K. Birkeland,et al.  Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.

[102]  G. Salles,et al.  Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[103]  W. Goessling,et al.  Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. , 2008, Gastroenterology.

[104]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[105]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[106]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[107]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[108]  E Moser,et al.  Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment , 2008, NMR in biomedicine.

[109]  H. Tilg,et al.  Inflammatory Mechanisms in the Regulation of Insulin Resistance , 2008, Molecular medicine.

[110]  G. Lippi,et al.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients , 2008, Diabetologia.

[111]  J. Sastre,et al.  Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia–reperfusion injury , 2008, Gut.

[112]  B. S. Mohammed,et al.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[113]  K. Pietiläinen,et al.  Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[114]  M. McKee,et al.  Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.

[115]  X. Papademetris,et al.  The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome , 2007, Proceedings of the National Academy of Sciences.

[116]  Manisha Talim,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[117]  M. Kivimäki,et al.  Does personality predict mortality? Results from the GAZEL French prospective cohort study. , 2007, International journal of epidemiology.

[118]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[119]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[120]  Michael Roden,et al.  Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[121]  J. Talwalkar,et al.  The spectrum of nonalcoholic fatty liver disease , 2005 .

[122]  S. Haffner,et al.  Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. , 2005, Diabetes.

[123]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[124]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[125]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.

[126]  A. Hevener,et al.  IKK-β links inflammation to obesity-induced insulin resistance , 2005, Nature Medicine.

[127]  C. Cobelli,et al.  Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. , 2004, Diabetes.

[128]  A. Lazenby,et al.  Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease , 2004, Hepatology.

[129]  D. Befroy,et al.  Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.

[130]  P. Iozzo,et al.  Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. , 2004, The Journal of clinical endocrinology and metabolism.

[131]  Donald D Hensrud,et al.  Splanchnic lipolysis in human obesity. , 2004, The Journal of clinical investigation.

[132]  R. Unger.  Lipid overload and overflow: metabolic trauma and the metabolic syndrome , 2003, Trends in Endocrinology & Metabolism.

[133]  J. Arenas,et al.  Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis , 2003, Hepatology.

[134]  D. Jacobs,et al.  Gamma-glutamyltransferase and diabetes—a 4 year follow-up study , 2003, Diabetologia.

[135]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[136]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[137]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[138]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[139]  H. Tilg,et al.  Cytokines in alcoholic and nonalcoholic steatohepatitis. , 2000, The New England journal of medicine.

[140]  P. Thuluvath,et al.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case‐control study , 2000, Hepatology.

[141]  G. Shulman,et al.  Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. , 2000, Diabetes.

[142]  C. Baird.  The pilot study. , 2000, Orthopedic nursing.

[143]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[144]  H. Cortez‐Pinto,et al.  Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.

[145]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[146]  B. Spiegelman,et al.  Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. , 1994, The Journal of clinical investigation.

[147]  B. Morris,et al.  Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals. , 1994, The Journal of clinical investigation.

[148]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[149]  Brian Davies,et al.  European Association for the Study of Diabetes , 1984, Diabetologia.

[150]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[151]  Debbie,et al.  The British Women’s Heart and Health Study and meta-analysis , 2018 .

[152]  N. Kurysheva,et al.  A case–control study , 2018 .

[153]  M. Cole,et al.  Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. , 2014, Journal of hepatology.

[154]  A. Günther,et al.  a pilot trial , 2012 .

[155]  Laurie J. Pencille,et al.  The Chest Pain Choice Decision Aid: A Randomized Trial , 2012, Circulation. Cardiovascular quality and outcomes.

[156]  H. Tilg,et al.  Adipose and Liver Expression of Interleukin (IL)-1 Family Members in Morbid Obesity and Effects of Weight Loss , 2011, Molecular medicine.

[157]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[158]  M. Ebato,et al.  Prospective Study , 2022, The SAGE Encyclopedia of Research Design.

[159]  M. Rigoulet,et al.  Mitochondrial adaptations to steatohepatitis induced by a methionine- and choline-deficient diet. , 2008, American journal of physiology. Endocrinology and metabolism.

[160]  J. Lakerveld,et al.  BMC Endocrine Disorders BioMed Central Study protocol , 2008 .

[161]  D. Moller,et al.  Metabolic syndrome: a clinical and molecular perspective. , 2005, Annual review of medicine.

[162]  Sang-hun Park.  Expanding the Natural History of Nonalcoholic Steatohepatitis: from Cryptogenic Cirrhosis to Hepatocellular Carcinoma , 2003 .

[163]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[164]  Ken W. Woodhouse,et al.  The Clinical Perspective , 1994 .

[165]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[166]  H. Thaler.  [Fatty liver, its causes and concomitant diseases]. , 1962, Deutsche medizinische Wochenschrift.